SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
14,766Targets
453Trials
84Drugs
7Datasets
6,987Sources
64,683Claims
72,052Evidence
29,649Hypotheses
DRUGphase1small molecule

cinnatrarx p38a inhibitor

Mechanism

p38α MAPK inhibitor. Targets stress-kinase signaling implicated in SMA motor neuron loss. Spinout from Columbia University / NU collaboration.

Related claims (0)

No claims matched “cinnatrarx p38a inhibitor” in free-text search.

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center